OraSure Technologies Inc. (OSUR) Given a $10.00 Price Target at Canaccord Genuity
OraSure Technologies Inc. (NASDAQ:OSUR) received a $10.00 price target from stock analysts at Canaccord Genuity in a report issued on Monday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target suggests a potential upside of 18.62% from the stock’s current price.
Several other analysts have also recently issued reports on the company. Stephens upgraded OraSure Technologies from an “equal weight” rating to an “overweight” rating in a research report on Monday, August 29th. Jefferies Group cut their target price on OraSure Technologies from $8.50 to $8.00 and set a “buy” rating for the company in a research report on Thursday, August 4th. TheStreet upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research report on Tuesday, August 30th. Finally, BTIG Research cut OraSure Technologies from a “buy” rating to a “neutral” rating and set a $8.00 target price for the company. in a research report on Monday, September 19th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $8.58.
Shares of OraSure Technologies (NASDAQ:OSUR) traded up 0.59% during trading on Monday, reaching $8.48. The company’s stock had a trading volume of 303,145 shares. OraSure Technologies has a 12-month low of $5.09 and a 12-month high of $9.05. The company has a 50 day moving average of $7.92 and a 200-day moving average of $7.50. The stock has a market cap of $472.59 million, a price-to-earnings ratio of 28.27 and a beta of 1.50.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 2nd. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.04. The business earned $32.25 million during the quarter, compared to analysts’ expectations of $31.45 million. OraSure Technologies had a return on equity of 10.27% and a net margin of 13.70%. The business’s quarterly revenue was up 7.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.03 earnings per share. Analysts forecast that OraSure Technologies will post $0.29 EPS for the current year.
In other news, CEO Douglas A. Michels sold 30,893 shares of the firm’s stock in a transaction that occurred on Wednesday, November 23rd. The stock was sold at an average price of $9.02, for a total value of $278,654.86. Following the completion of the sale, the chief executive officer now directly owns 731,898 shares of the company’s stock, valued at approximately $6,601,719.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Douglas A. Michels sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, September 26th. The shares were sold at an average price of $8.22, for a total value of $205,500.00. Following the completion of the sale, the chief executive officer now directly owns 756,898 shares of the company’s stock, valued at $6,221,701.56. The disclosure for this sale can be found here. Corporate insiders own 7.80% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Emerald Acquisition Ltd. bought a new stake in OraSure Technologies during the second quarter valued at about $363,000. Bank of New York Mellon Corp raised its stake in OraSure Technologies by 166.0% in the second quarter. Bank of New York Mellon Corp now owns 715,490 shares of the company’s stock valued at $4,229,000 after buying an additional 446,468 shares during the last quarter. Hood River Capital Management LLC raised its stake in OraSure Technologies by 25.7% in the second quarter. Hood River Capital Management LLC now owns 907,759 shares of the company’s stock valued at $5,365,000 after buying an additional 185,722 shares during the last quarter. HealthInvest Partners AB raised its stake in OraSure Technologies by 17.3% in the second quarter. HealthInvest Partners AB now owns 475,771 shares of the company’s stock valued at $2,812,000 after buying an additional 70,000 shares during the last quarter. Finally, Smith Asset Management Group LP bought a new stake in OraSure Technologies during the second quarter valued at about $2,357,000. 81.91% of the stock is owned by institutional investors and hedge funds.
OraSure Technologies Company Profile
OraSure Technologies, Inc (OraSure) is involved in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its technologies, as well as other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types.
Receive News & Stock Ratings for OraSure Technologies Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies Inc. and related stocks with our FREE daily email newsletter.